These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 23066315

  • 1. Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis.
    Heinzow HS, Lenz P, Köhler M, Reinecke F, Ullerich H, Domschke W, Domagk D, Meister T.
    World J Gastroenterol; 2012 Oct 07; 18(37):5211-8. PubMed ID: 23066315
    [Abstract] [Full Text] [Related]

  • 2. Long-term clinical outcome and survival predictors in patients with cirrhosis after 10-mm-covered transjugular intrahepatic portosystemic shunt.
    Tejedor-Tejada J, Fuentes-Valenzuela E, García-Pajares F, Nájera-Muñoz R, Almohalla-Álvarez C, Sánchez-Martín F, Calero-Aguilar H, Villacastín-Ruiz E, Pintado-Garrido R, Sánchez-Antolín G.
    Gastroenterol Hepatol; 2021 Nov 07; 44(9):620-627. PubMed ID: 33249114
    [Abstract] [Full Text] [Related]

  • 3. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
    Teng D, Zuo H, Liu L, Dong J, Ding L.
    Virol J; 2018 Oct 01; 15(1):151. PubMed ID: 30285813
    [Abstract] [Full Text] [Related]

  • 4. Transjugular Intrahepatic Porto-Systemic Shunt in Patients with Liver Cirrhosis and Model for End-Stage Liver Disease ≥15.
    Ascha M, Hanouneh M, S Ascha M, Zein NN, Sands M, Lopez R, Hanouneh IA.
    Dig Dis Sci; 2017 Feb 01; 62(2):534-542. PubMed ID: 27154510
    [Abstract] [Full Text] [Related]

  • 5. Predictors of Shunt Dysfunction and Overall Survival in Patients with Variceal Bleeding Treated with Transjugular Portosystemic Shunt Creation Using the Fluency Stent Graft.
    Wan YM, Li YH, Xu Y, Wu HM, Li YC, Wu XN, Yang JH.
    Acad Radiol; 2018 Jul 01; 25(7):925-934. PubMed ID: 29373208
    [Abstract] [Full Text] [Related]

  • 6. Comparison of transjugular intrahepatic portosystemic shunt (TIPS) alone versus TIPS combined with embolotherapy in advanced cirrhosis: a retrospective study.
    Xiao T, Chen L, Chen W, Xu B, Long Q, Li R, Li L, Peng Z, Fang D, Wang R.
    J Clin Gastroenterol; 2011 Aug 01; 45(7):643-50. PubMed ID: 21301360
    [Abstract] [Full Text] [Related]

  • 7. Decision making for transjugular intrahepatic portosystemic stent shunt in refractory ascites and variceal bleeding: MELD, or not MELD, that is the question.
    Pitton MB, Zimmermann T, Mildenberger P, Weinmann A, Kloeckner R, Düber C, Mittler J, Hoppe-Lotichius M, Otto G.
    Eur J Gastroenterol Hepatol; 2021 Dec 01; 33(1S Suppl 1):e214-e222. PubMed ID: 33230020
    [Abstract] [Full Text] [Related]

  • 8. Incrementally Expandable Transjugular Intrahepatic Portosystemic Shunts: Single-Center Experience.
    Cui J, Smolinski SE, Liu F, Xu D, Dulaimy K, Irani Z.
    AJR Am J Roentgenol; 2018 Feb 01; 210(2):438-446. PubMed ID: 29261352
    [Abstract] [Full Text] [Related]

  • 9. Long-term effects and complications of the transjugular intrahepatic portosystemic shunt: a single-centre experience.
    Kraglund F, Jepsen P, Amanavicius N, Aagaard NK.
    Scand J Gastroenterol; 2019 Jul 01; 54(7):899-904. PubMed ID: 31203699
    [Abstract] [Full Text] [Related]

  • 10. Right atrial pressure may impact early survival of patients undergoing transjugular intrahepatic portosystemic shunt creation.
    Parvinian A, Bui JT, Knuttinen MG, Minocha J, Gaba RC.
    Ann Hepatol; 2014 Jul 01; 13(4):411-9. PubMed ID: 24927612
    [Abstract] [Full Text] [Related]

  • 11. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.
    Tan HK, James PD, Sniderman KW, Wong F.
    J Gastroenterol Hepatol; 2015 Feb 01; 30(2):389-95. PubMed ID: 25168607
    [Abstract] [Full Text] [Related]

  • 12. Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding.
    Walter A, Rudler M, Olivas P, Moga L, Trépo E, Robic MA, Ollivier-Hourmand I, Baiges A, Sutter O, Bouzbib C, Peron JM, Le Pennec V, Ganne-Carrié N, Garcia-Pagán JC, Mallet M, Larrue H, Dao T, Thabut D, Hernández-Gea V, Nault JC, Bureau C, Allaire M, Salvage TIPS Group.
    Hepatology; 2021 Oct 01; 74(4):2085-2101. PubMed ID: 34018627
    [Abstract] [Full Text] [Related]

  • 13. [Preliminary application of transjugular intrahepatic portosystemic shunt in individualized treatment of patients with cirrhotic portal hypertension complicated with refractory ascites and variceal hemorrhage].
    Jiang MM, Xu H, Zhang QQ, Wei N, Xu W, Cui YF, Liu HT, Zu MH, Wang WL, Gao ZK.
    Zhonghua Yi Xue Za Zhi; 2019 Dec 17; 99(47):3737-3740. PubMed ID: 31874500
    [Abstract] [Full Text] [Related]

  • 14. Effect of initial stent position on patency of transjugular intrahepatic portosystemic shunt.
    Luo SH, Chu JG, Huang H, Yao KC.
    World J Gastroenterol; 2017 Jul 14; 23(26):4779-4787. PubMed ID: 28765699
    [Abstract] [Full Text] [Related]

  • 15. [Comparison of the curative effect of transjugular intrahepatic portosystemic shunt with expanded polytetrafluoroethylene-covered stent and drug combined with gastroscopy as the secondary prevention of esophageal -gastric variceal bleeding in portal hypertension].
    Lin ZP, Chen SL, Wang JY, Liu F, Tan Q, Peng QF, Zhao JB.
    Zhonghua Gan Zang Bing Za Zhi; 2020 Aug 20; 28(8):672-678. PubMed ID: 32911906
    [Abstract] [Full Text] [Related]

  • 16. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation.
    Praktiknjo M, Abu-Omar J, Chang J, Thomas D, Jansen C, Kupczyk P, Schepis F, Garcia-Pagan JC, Merli M, Meyer C, Strassburg CP, Pieper CC, Trebicka J.
    JHEP Rep; 2021 Jun 20; 3(3):100264. PubMed ID: 34013182
    [Abstract] [Full Text] [Related]

  • 17. Early and long-term clinical and radiological follow-up results of expanded-polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunt procedures.
    Maleux G, Nevens F, Wilmer A, Heye S, Verslype C, Thijs M, Wilms G.
    Eur Radiol; 2004 Oct 20; 14(10):1842-50. PubMed ID: 15221261
    [Abstract] [Full Text] [Related]

  • 18. Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites: a retrospective cohort study.
    Maleux G, Perez-Gutierrez NA, Evrard S, Mroue A, Le Moine O, Laleman W, Nevens F.
    Acta Gastroenterol Belg; 2010 Oct 20; 73(3):336-41. PubMed ID: 21086935
    [Abstract] [Full Text] [Related]

  • 19. Expanded polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunts in cirrhotic patients: Long-term patency and clinical outcome results.
    Geeroms B, Laleman W, Laenen A, Heye S, Verslype C, van der Merwe S, Nevens F, Maleux G.
    Eur Radiol; 2017 May 20; 27(5):1795-1803. PubMed ID: 27629421
    [Abstract] [Full Text] [Related]

  • 20. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
    Dissegna D, Sponza M, Falleti E, Fabris C, Vit A, Angeli P, Piano S, Cussigh A, Cmet S, Toniutto P.
    Eur J Gastroenterol Hepatol; 2019 May 20; 31(5):626-632. PubMed ID: 30550458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.